
    
      This efficacy and safety research plan to explore the use of Apatinib combined with
      Vinorelbine to driven gene mutation negative three line and three line later non-small cell
      lung cancer.According to the result of TAX317,the investigators expect the effective rate is
      20% and 80% of degree of assurance.Single arm bilateral experiment's sample size is
      calculated 27, according to 10% censoring,the expected sample size is 30.
    
  